Chat with us, powered by LiveChat

Driving confidence in decisions: Updates and advancements in the Lhasa Carcinogenicity Database

Lhasa Limited is delighted to unveil new data in the Lhasa Carcinogenicity Database (LCDB), to support enhanced carcinogenicity risk assessments.

The LCDB, built upon the retired Carcinogenic Potency Database (CPDB) established by Lois Gold and her team, is a freely available source of long-term carcinogenicity study data. Recognising the importance of the CPDB resource, we Lhasa acted to secure its long-term availability, and have been dedicated to ongoing enhancements, ensuring its continuous development for the benefit of the public.

The redesigned interface incorporates newly calculated Lhasa TD50 values, as a measure of potency in cancer risk assessment, derived from the original data provided by Lois Gold and her team. This not only ensures transparency, but also establishes a methodological continuity from the CPDB, offering a clear and consistent approach to calculating TD50 values from experimental data.


Exploring the latest updates to the LCDB


The latest advancements to the LCDB include a breadth of new scientific updates and data enhancements designed to help users make more confident decisions in their carcinogenicity assessments.

Lhasa have introduced 2,235 test compounds, bringing the total to 3,961. Furthermore, 11,787 new study records have been incorporated, expanding the database to 19,532 in total. Significant updates have been made to the TD50 model to enhance its performance bolstering its robustness and accuracy.

As a not-for-profit organisation, Lhasa is dedicated to maintaining continuous availability and supporting users with improved decision-making and increased productivity. The latest software improvements, including the addition of a new study information section that incorporates the Lhasa reliability score, help to create a more comprehensive and user-friendly experience.

We recently held our webinar ‘Harnessing cutting-edge carcinogenicity data to support toxicity assessments’, in which Lhasa Product Owner, Monica Abreu and Senior Scientist, Andrew Thresher, discussed the latest updates to the database. Watch the webinar recording to learn more.

The LCDB is available to access now!

Please get in touch to learn more about how Lhasa can support your carcinogenicity assessments.